Published in European Urology Oncology, the study is a one-year follow up to early outcomes data that were published in 2019 in 101 patients at Amsterdam University Medical Center who were treated with ViewRay's MRIdian radiation therapy system, which uses an onboard MRI scanner to guide treatment.
The one-year data echoed the early-outcomes findings that reported the continued absence of genitourinary or gastrointestinal toxicities at grade 3 or higher in men treated with MRIdian for prostate cancer.
The patients received MRIdian treatment in five fractions of 7.25 Gy. Thanks to the system's MRI guidance, the treatments did not use implanted markers or tissue spacers between rectum and prostate. This eliminates the need for an invasive procedure and can potentially reduce complications, according to ViewRay.
ViewRay pointed out that the positive results were achieved in a patient cohort considered to have complex disease, with 59% categorized as high risk.
Copyright © 2020 AuntMinnieEurope.com